3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Gastrointestinal
1
Conditions
Prostatic Neoplasms
11
Lung Neoplasms
7
Colonic Neoplasms
5
Pancreatic Neoplasms
3
Pain, Postoperative
3
Inflammatory Bowel Diseases
3
Diverticulitis
3
Carcinoma, Hepatocellular
3
Urinary Bladder Neoplasms
2
Male Urogenital Diseases
2
Leiomyoma
2
Inflammation
2
Carcinoma, Non-Small-Cell Lung
2
Agnosia
2
Abdominal Cancer
2
Unspecified Adult Solid Tumor, Protocol Specific
1
Thyroid Neoplasms
1
Stomatitis
1
Stomach Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Smoking Cessation
1
Skin Neoplasms
1
Shoulder Pain
1
Respiration Disorders
1
Psychological Well-Being
1
Postoperative Complications
1
Post-thoracotomy Pain Syndrome
1
Pleural Diseases
1
Neoplasms
1
Mouth Neoplasms
1
Interventions
Cisplatin
109
Radiotherapy
100
Fluorouracil
90
Paclitaxel
75
Oxaliplatin
63
Docetaxel
56
Carboplatin
55
Irinotecan
41
Esophagectomy
41
Leucovorin
40
Capecitabine
39
Radiation
36
Surgical Procedures, Operative
35
Drug Therapy
31
Neoadjuvant Therapy
25
Chemoradiotherapy
18
Cetuximab
18
S 1 (combination)
17
pembrolizumab
16
camrelizumab
16
Nivolumab
15
Magnetic Resonance Spectroscopy
15
Bevacizumab
15
Blood Specimen Collection
14
Surveys and Questionnaires
12
Radiotherapy, Intensity-Modulated
12
Immunotherapy
11
Epirubicin
11
Biopsy
11
Trastuzumab
10
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
OTHER
×
Esophageal Neoplasms
×
Tea
×
Clear all
NCT04871412
2026-01-30
POISE
Ottawa Hospital Research Institute
Phase 3
Recruiting
20 enrolled